biostudies-literatureUnknown15(11)Ruan KThis prospective observational study investigated the efficacy of pembrolizumab administered as first-line therapy and the survival outcomes of continuing or combining it with other agents after disease progression in patients with stage IV non-small cell lung cancer (NSCLC). A total of 63 patients who experienced disease progression following pembrolizumab-based first-line treatment between February 2019 and July 2024 were prospectively enrolled. Patients were randomized into two cohorts based on treatment strategy: a treated beyond progression (TBP) group (n = 39) to receive continued pembrolizumab monotherapy or pembrolizumab-based combination regimens after disease progression, and a non-TBP (NTBP) group (n = 24), which discontinued pembrolizumab upon progression. The primary endpoint American journal of cancer research4934-4944https://www.ebi.ac.uk/biostudies/studies/S-EPMC12696522biostudies-literatureEfficacy of continuing pembrolizumab after progression on first-line treatment in stage IV non-small cell lung cancer: a prospective real-world study.PMC12696522Chen PShao JWang BLv XQu JHan ZWu DRuan KZheng JDing YHuang WSun DTang YWu XXu YZhou JfalseEfficacy of continuing pembrolizumab after progression on first-line treatment in stage IV non-small cell lung cancer: a prospective real-world study.This prospective observational study investigated the efficacy of pembrolizumab administered as first-line therapy and the survival outcomes of continuing or combining it with other agents after disease progression in patients with stage IV non-small cell lung cancer (NSCLC). A total of 63 patients who experienced disease progression following pembrolizumab-based first-line treatment between February 2019 and July 2024 were prospectively enrolled. Patients were randomized into two cohorts based on treatment strategy: a treated beyond progression (TBP) group (n = 39) to receive continued pembrolizumab monotherapy or pembrolizumab-based combination regimens after disease progression, and a non-TBP (NTBP) group (n = 24), which discontinued pembrolizumab upon progression. The primary endpoint 2025-01-01T00:00:00Z20252026-06-06T03:55:25.388Z2026-05-25T03:12:00.785ZS-EPMC126965224139528110.62347/GFTO644010.62347/gfto6440